The agency, Health Canada, issued guidance to study the off-label uses of different drugs in clinical trials.
According to the current regulations from Health Canada, the drugs purchased for clinical trials for their off-label benefits to be designated as “investigational drugs”.
Under new guidelines, any given treatment from sponsors will go through a series of questions from Canadian officials before getting the “investigational drug tag”. Following questions can be asked:
· Is the safety profile established for the drug when used off-label; · For what measures, it is used in clinical trials; · Is there any risks and benefits related to off-label use of drugs; · Is the drug registration already done in Canada; · Will the trial doses be bought in Canada; and · Does the off-label use increase chances of fatal risks.
The off-label drug’s compliance notice or Drug Identification number needs to be submitted by the sponsor and explanation for its original indication is also given.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like